Use of D-allose as an immunosuppressive agent
US5620960A · kind A · utility
4Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 1994 |
| Grant date | Apr 15, 1997 |
| Priority date | — |
| Expiry date | Aug 15, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7004
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
D-allose has been found to substantially inhibit segmented neutrophil production and to lower platelet counts during in vivo trials, without other significant detrimental clinical effects. Such pharmacological activity makes D-allose a good candidate for treatment, either alone or as an adjuvant, of such conditions as chronic myelogenous leukemia. It also holds promise in reducing thrombus formation during post-operative periods, especially in combination with other anti-clotting drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.